Stock Track | Krystal Biotech Soars 5.61% Pre-Market on Stellar Q4 Earnings and Positive Analyst Outlook

Stock Track

20 Feb

Krystal Biotech Inc. (KRYS) witnessed a remarkable 5.61% surge in its stock price during the pre-market trading session on Thursday, February 20th, 2025. This significant upward movement was fueled by the company's robust financial performance in the fourth quarter of 2024 and an optimistic outlook from a prominent analyst.

Krystal Biotech reported stellar earnings for Q4 2024 and the full year, driven by the successful launch of its flagship product, VYJUVEK, for the treatment of dystrophic epidermolysis bullosa (DEB). The company achieved net income per share of $3.12 for the full year 2024, a substantial increase from $0.40 in the previous year, marking six consecutive quarters of positive earnings growth.

In Q4 2024, Krystal Biotech generated net VYJUVEK revenue of $91.1 million, contributing to a total revenue of $290.5 million for the year. The company maintained a robust gross margin of 95% during the quarter, showcasing its operational efficiency and strong financial position, with $749.6 million in total cash and investments at the end of Q4 2024.

In addition to the impressive financial results, Citi analyst Yigal Nochomovitz raised the firm's price target on Krystal Biotech to $215 from $206, while maintaining a Neutral rating. Nochomovitz's positive outlook, coupled with the company's strong earnings and revenue growth, fueled investor confidence, driving the stock's pre-market surge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1196593767"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1196593767\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1196593767?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-20 23:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196593767","market":"us","top_or_hot":-1,"title":"Stock Track | Krystal Biotech Soars 5.61% Pre-Market on Stellar Q4 Earnings and Positive Analyst Outlook","media":"Stock Track","content":"<p>Krystal Biotech Inc. (KRYS) witnessed a remarkable 5.61% surge in its stock price during the pre-market trading session on Thursday, February 20th, 2025. This significant upward movement was fueled by the company's robust financial performance in the fourth quarter of 2024 and an optimistic outlook from a prominent analyst.</p>\n\n<p>Krystal Biotech reported stellar earnings for Q4 2024 and the full year, driven by the successful launch of its flagship product, VYJUVEK, for the treatment of dystrophic epidermolysis bullosa (DEB). The company achieved net income per share of $3.12 for the full year 2024, a substantial increase from $0.40 in the previous year, marking six consecutive quarters of positive earnings growth.</p>\n\n<p>In Q4 2024, Krystal Biotech generated net VYJUVEK revenue of $91.1 million, contributing to a total revenue of $290.5 million for the year. The company maintained a robust gross margin of 95% during the quarter, showcasing its operational efficiency and strong financial position, with $749.6 million in total cash and investments at the end of Q4 2024.</p>\n\n<p>In addition to the impressive financial results, Citi analyst Yigal Nochomovitz raised the firm's price target on Krystal Biotech to $215 from $206, while maintaining a Neutral rating. Nochomovitz's positive outlook, coupled with the company's strong earnings and revenue growth, fueled investor confidence, driving the stock's pre-market surge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Krystal Biotech Soars 5.61% Pre-Market on Stellar Q4 Earnings and Positive Analyst Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Krystal Biotech Soars 5.61% Pre-Market on Stellar Q4 Earnings and Positive Analyst Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-20 23:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Krystal Biotech Inc. (KRYS) witnessed a remarkable 5.61% surge in its stock price during the pre-market trading session on Thursday, February 20th, 2025. This significant upward movement was fueled by the company's robust financial performance in the fourth quarter of 2024 and an optimistic outlook from a prominent analyst.</p>\n\n<p>Krystal Biotech reported stellar earnings for Q4 2024 and the full year, driven by the successful launch of its flagship product, VYJUVEK, for the treatment of dystrophic epidermolysis bullosa (DEB). The company achieved net income per share of $3.12 for the full year 2024, a substantial increase from $0.40 in the previous year, marking six consecutive quarters of positive earnings growth.</p>\n\n<p>In Q4 2024, Krystal Biotech generated net VYJUVEK revenue of $91.1 million, contributing to a total revenue of $290.5 million for the year. The company maintained a robust gross margin of 95% during the quarter, showcasing its operational efficiency and strong financial position, with $749.6 million in total cash and investments at the end of Q4 2024.</p>\n\n<p>In addition to the impressive financial results, Citi analyst Yigal Nochomovitz raised the firm's price target on Krystal Biotech to $215 from $206, while maintaining a Neutral rating. Nochomovitz's positive outlook, coupled with the company's strong earnings and revenue growth, fueled investor confidence, driving the stock's pre-market surge.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRYS","symbol_name":"Krystal Biotech Inc.","start_time":0,"source_url":"","article_id":"1196593767","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196593767","pubTimestamp":1740063669,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Krystal Biotech Inc.  witnessed a remarkable 5.61% surge in its stock price during the pre-market trading session on Thursday, February 20th, 2025. This significant upward movement was fueled by the company's robust financial performance in the fourth quarter of 2024 and an optimistic outlook from a prominent analyst.Krystal Biotech reported stellar earnings for Q4 2024 and the full year, driven by the successful launch of its flagship product, VYJUVEK, for the treatment of dystrophic epidermoly","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRYS":"Krystal Biotech Inc."},"translate_title":"股票轨迹Krystal Biotech盘前飙升5.61%，第四季度盈利出色，分析师前景乐观","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRYS":1},"content_text":"Krystal Biotech Inc. (KRYS) witnessed a remarkable 5.61% surge in its stock price during the pre-market trading session on Thursday, February 20th, 2025. This significant upward movement was fueled by the company's robust financial performance in the fourth quarter of 2024 and an optimistic outlook from a prominent analyst.\nKrystal Biotech reported stellar earnings for Q4 2024 and the full year, driven by the successful launch of its flagship product, VYJUVEK, for the treatment of dystrophic epidermolysis bullosa (DEB). The company achieved net income per share of $3.12 for the full year 2024, a substantial increase from $0.40 in the previous year, marking six consecutive quarters of positive earnings growth.\nIn Q4 2024, Krystal Biotech generated net VYJUVEK revenue of $91.1 million, contributing to a total revenue of $290.5 million for the year. The company maintained a robust gross margin of 95% during the quarter, showcasing its operational efficiency and strong financial position, with $749.6 million in total cash and investments at the end of Q4 2024.\nIn addition to the impressive financial results, Citi analyst Yigal Nochomovitz raised the firm's price target on Krystal Biotech to $215 from $206, while maintaining a Neutral rating. Nochomovitz's positive outlook, coupled with the company's strong earnings and revenue growth, fueled investor confidence, driving the stock's pre-market surge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}